PMVP
8:00 AM
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New
Presentation / Abstract • Phase 2Oral presentation Sun, Apr 12, 2026pmvpharma.com